安序源科技赴港IPO：连续两年亏损，阿斯利康中金、云锋基金等参投

Core Viewpoint - Axbio International Limited, a biotechnology company focused on integrated circuit technology, has filed for an IPO on the Hong Kong Stock Exchange, despite reporting consecutive losses over the past two years and not generating revenue from its research products [1][2]. Company Overview - Axbio International Limited was established in 2016 and specializes in molecular diagnostic products, a next-generation electrochemical long-read sequencing platform (EL-NGS), and biochips, along with related services [2]. - The company's product pipeline includes a microarray chip analyzer, two EL-NGS gene sequencers, and various testing kits [4]. Financial Performance - The company reported no revenue in 2023, with projected revenue of $47,900 in 2024, primarily from the sale of AxiLona AXP-100 for research purposes [4]. - Financial data for 2023 and 2024 shows: - Revenue: $479,000 in 2024 - Cost of Sales: $175,000 in 2024 - Gross Profit: $304,000 in 2024 - Other Income: $1,935,000 in 2023 and $2,063,000 in 2024 - Total Loss: $22,856,000 in 2023 and $23,466,000 in 2024 [5]. - The losses are primarily attributed to research and administrative expenses, with R&D expenditures of $15.3 million in 2023 and $11.4 million in 2024 [6]. Shareholding and Investment - The company was founded by Dr. Hui Tian and Dr. Igor Ivanov, with Dr. Tian holding 30.44% of the shares, making him the largest single shareholder [7]. - Axbio has received investments from notable institutions including AstraZeneca, CICC, and Yunfeng Capital [9]. Use of IPO Proceeds - The funds raised from the IPO will be allocated for the further development, commercialization, and production of core products AxiLona EL-100 and AxiLona AXP-100, as well as the development of AxiLona AXP-1000 and other pipeline products [9].